CBP Bromodomain Inhibition Rescues Mice From Lethal Sepsis Through Blocking HMGB1-Mediated Inflammatory Responses
Open Access
- 2 February 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11
Abstract
CREB binding protein (CBP), a transcriptional coactivator and acetyltransferase, is involved in the pathogenesis of inflammation-related diseases. High mobility group box-1 protein (HMGB1) is a critical mediator of lethal sepsis, which has prompted investigation for the development of new treatment for inflammation. Here, we report that the potent and selective inhibition of CBP bromodomain by SGC-CBP30 blocks HMGB1-mediated inflammatory responses in vitro and in vivo. Our data suggest that CBP bromodomain inhibition suppresses LPS-induced expression and release of HMGB1, when the inhibitor was given 8 h post LPS stimulation; moreover, CBP bromodomain inhibition attenuated pro-inflammatory activity of HMGB1. Furthermore, our findings provide evidence that SGC-CBP30 down-regulated rhHMGB1-induced activation of MAPKs and NF-κB signaling by triggering the reactivation of protein phosphatase 2A (PP2A) and the stabilization of MAPK phosphatase 1 (MKP-1). Collectively, these results suggest that CBP bromodomain could serve as a candidate therapeutic target for the treatment of lethal sepsis via inhibiting LPS-induced expression and release of HMGB1 and suppressing the pro-inflammatory activity of HMGB1.Keywords
This publication has 44 references indexed in Scilit:
- Cytokines in Sepsis: Potent Immunoregulators and Potential Therapeutic Targets—An Updated ViewMediators of Inflammation, 2013
- LPS Induces HMGB1 Relocation and Release by Activating the NF-κB-CBP Signal Transduction Pathway in the Murine Macrophage-Like Cell Line RAW264.7Journal of Surgical Research, 2012
- The biogenesis of active protein phosphatase 2A holoenzymes: a tightly regulated process creating phosphatase specificityThe FEBS Journal, 2012
- Bromodomains as therapeutic targetsExpert Reviews in Molecular Medicine, 2011
- HMGB1 activates nuclear factor-κB signaling by RAGE and increases the production of TNF-α in human umbilical vein endothelial cellsImmunobiology, 2010
- Pathological roles of MAPK signaling pathways in human diseasesBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2010
- NOVEL HMGB1-INHIBITING THERAPEUTIC AGENTS FOR EXPERIMENTAL SEPSISShock, 2009
- CBP/p300-mediated acetylation of histone H3 on lysine 56Nature, 2009
- Immunodesign of experimental sepsis by cecal ligation and punctureNature Protocols, 2008
- Spatial control of protein phosphatase 2A (de)methylationExperimental Cell Research, 2008